Massachusetts General Hospital, Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Hospital in Boston, Massachusetts
450 Brookline Ave, Boston, MA 02215
About Massachusetts General Hospital, Dana-Farber Cancer Institute
Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Celgene
7
Medical College of Wisconsin
7
National Heart, Lung, and Blood Institute (NHLBI)
3
CTI BioPharma
1
Eisai Inc.
1
Emory University
1
George Clinical Pty Ltd
1
Novartis Pharmaceuticals
1
OncoMed Pharmaceuticals, Inc.
1
Sarcoma Alliance for Research through Collaboration
1
Vanderbilt-Ingram Cancer Center
1
Clinical Trials at Massachusetts General Hospital, Dana-Farber Cancer Institute
During the past decade, Massachusetts General Hospital, Dana-Farber Cancer Institute conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 10 clinical trials were completed, i.e. on
average, 71.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
2008-10-01
2013-11-01
Completed
55
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
2008-12-01
2013-11-01
Completed
54
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
2009-04-01
2016-08-01
Completed
65
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
2010-05-01
2018-03-03
Completed
758
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
2011-10-13
2017-03-01
Terminated
30
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
2013-04-01
2017-05-01
Terminated
12
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
2013-04-01
2016-08-01
Completed
114
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Massachusetts General Hospital, Dana-Farber Cancer Institute" #1 sponsor was "Celgene" with 7 trials, followed by "Medical College of Wisconsin" with 7 trials
sponsored, "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials sponsored, "CTI BioPharma" with 1 trials sponsored and "Eisai Inc."
with 1 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Massachusetts General Hospital, Dana-Farber Cancer Institute"
#1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 9 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 8 trials as a collaborator, "National Marrow Donor Program" with 6 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Massachusetts General Hospital, Dana-Farber Cancer Institute
According to Clinical.Site data, the most researched conditions in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are
"Acute Leukemia" (3 trials), "Leukemia, Myeloid, Acute" (3 trials), "Lymphoma, B-Cell" (3 trials), "Lymphoma, Follicular" (3 trials) and "Lymphoma, Large B-Cell, Diffuse" (3 trials). Many other conditions were trialed in "Massachusetts General Hospital, Dana-Farber Cancer Institute" in a lesser frequency.
Clinical Trials Intervention Types at Massachusetts General Hospital, Dana-Farber Cancer Institute
Most popular intervention types in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are "Drug" (19 trials), "Procedure" (5 trials), "Biological" (3 trials), "Genetic" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Cyclophosphamide" (4 trials), "Methotrexate" (3 trials), "Tacrolimus" (3 trials), "CC-93538" (2 trials) and "Fludarabine" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Massachusetts General Hospital, Dana-Farber Cancer Institute
The vast majority of trials in "Massachusetts General Hospital, Dana-Farber Cancer Institute" are
24 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Massachusetts General Hospital, Dana-Farber Cancer Institute
Currently, there are NaN active trials in "Massachusetts General Hospital, Dana-Farber Cancer Institute".
undefined are not yet recruiting,
6 are recruiting,
6 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 11 completed trials in Massachusetts General Hospital, Dana-Farber Cancer Institute,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Massachusetts General Hospital, Dana-Farber Cancer Institute, 6 "Phase 1"
clinical trials were conducted, 11 "Phase 2" clinical
trials and 9 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".